Patents by Inventor Pingyu Ding

Pingyu Ding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TYROSINE KINASE INHIBITORS
    Publication number: 20190099411
    Abstract: Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, Y and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.
    Type: Application
    Filed: October 4, 2018
    Publication date: April 4, 2019
    Inventors: Sacha Holland, Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Rao Kolluri, Ihab Darwish, Esteban Masuda, Jiaxin Yu
  • 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use
    Patent number: 10233170
    Abstract: The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-? superfamily such as Nodal or Activin.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: March 19, 2019
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Donald Payan, Marina Gelman, Todd Kinsella
  • Substituted triazoles useful as Axl inhibitors
    Patent number: 10166216
    Abstract: Substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: January 1, 2019
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Dane Goff, Jing Zhang, Catherine Sylvain, Rajinder Singh, Sacha Holland, Jiaxin Yu, Thilo J. Heckrodt, Pingyu Ding
  • TGF-ß Inhibitors
    Publication number: 20180339979
    Abstract: Disclosed are aryl pyrimidine compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure (I) and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein A, Z, R and R? are as described herein. In certain embodiments, a compound disclosed herein inhibits the activity of one or more members of the TGF-? superfamily, and can be used to treat disease by blocking such activity.
    Type: Application
    Filed: March 29, 2016
    Publication date: November 29, 2018
    Inventors: Marina Gelman, Pingyu Ding, Todd Kinsella, Rajinder Singh, Somasekhar Bhamidipati, Jeffrey Clough
  • Tyrosine kinase inhibitors
    Patent number: 10130623
    Abstract: Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, Y and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: November 20, 2018
    Assignee: RIGEL PHARMACEUTICALS, INC.
    Inventors: Sacha Holland, Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Rao Kolluri, Ihab Darwish, Esteban Masuda, Jiaxin Yu
  • COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
    Publication number: 20180162848
    Abstract: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.
    Type: Application
    Filed: February 8, 2018
    Publication date: June 14, 2018
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Thilo J. Heckrodt, Yan Chen, Darren John McMurtrie, Vanessa Taylor, Rajinder Singh, Pingyu Ding, Rose Yen
  • GDF-8 inhibitors
    Patent number: 9981944
    Abstract: Disclosed are 2,2?-bipyridyl compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein R1, Z and n are as described herein. In certain embodiments, a compound disclosed herein inhibits GDF8, and can be used to treat disease by blocking GDF8 signaling.
    Type: Grant
    Filed: February 15, 2016
    Date of Patent: May 29, 2018
    Assignees: RIGEL PHARMACEUTICALS, INC, BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Pingyu Ding, Marina Gelman, Todd Kinsella, Rajinder Singh, Somasekhar Bhamidipati, Upender Velaparthi, Robert M. Borzilleri, Hasibur Rahaman, Jayakumar Sankara Warrier
  • Compositions and methods for inhibition of the JAK pathway
    Patent number: 9920041
    Abstract: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: March 20, 2018
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Thilo J. Heckrodt, Yan Chen, Darren John McMurtrie, Vanessa Taylor, Rajinder Singh, Pingyu Ding, Rose Yen
  • GDF-8 inhibitors
    Patent number: 9878992
    Abstract: Described are GCF-8 inhibitors of the formula (I), and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R5, R6, X and Z are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for inhibiting GDF-8 in a cell and methods for treating a patient suffering from a disease or disorder, wherein the patient would therapeutically benefit from an increase in mass or strength of muscle tissue.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: January 30, 2018
    Assignee: RIGEL PHARMACEUTICALS, INC.
    Inventors: Somasekhar Bhamidipati, Marina Gelman, Pingyu Ding, Rajinder Singh, Jeffrey Clough, Todd Kinsella, Donald Payan
  • TYROSINE KINASE INHIBITORS
    Publication number: 20180008589
    Abstract: Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, Y and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.
    Type: Application
    Filed: July 10, 2017
    Publication date: January 11, 2018
    Inventors: Sacha Holland, Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Rao Kolluri, Ihab Darwish, Esteban Masuda, Jiaxin Yu
  • Kinase inhibitors and their uses
    Patent number: 9834568
    Abstract: The present disclosure provides compounds that inhibit protein kinases, such as JAK, Axl, or Syk kinases, compositions comprising the compounds and methods of using the compounds to inhibit protein kinase and treat and/or prevent diseases associated with inappropriate kinase activity.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: December 5, 2017
    Assignee: RIGEL PHARMACEUTICALS, INC.
    Inventors: Pingyu Ding, Ankush Argade, Dane Goff, Rajinder Singh, Esteban Masuda, Vanessa Taylor, Sacha Holland
  • GDF-8 Inhibitors
    Publication number: 20170342048
    Abstract: Described are GCF-8 inhibitors of the formula (I), and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R5, R6, X and Z are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for inhibiting GDF-8 in a cell and methods for treating a patient suffering from a disease or disorder, wherein the patient would therapeutically benefit from an increase in mass or strength of muscle tissue.
    Type: Application
    Filed: July 13, 2017
    Publication date: November 30, 2017
    Inventors: Somasekhar Bhamidipati, Marina Gelman, Pingyu Ding, Rajinder Singh, Jeffrey Clough, Todd Kinsella, Donald Payan
  • COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
    Publication number: 20170158683
    Abstract: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.
    Type: Application
    Filed: February 22, 2017
    Publication date: June 8, 2017
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Thilo J. Heckrodt, Yan Chen, Darren John McMurtrie, Vanessa Taylor, Rajinder Singh, Pingyu Ding, Rose Yen
  • N-heteroaryl substituted triazoles and N-heteroaryl substituted triazoles useful as Axl inhibitors
    Patent number: 9650391
    Abstract: N3-Heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.
    Type: Grant
    Filed: December 28, 2007
    Date of Patent: May 16, 2017
    Assignee: Rigel Pharmaceuticals Inc.
    Inventors: Pingyu Ding, Dane Goff, Jing Zhang, Rajinder Singh, Sacha Holland, Jiaxin Yu, Thilo J. Heckrodt, Joane Litvak
  • Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases
    Patent number: 9624229
    Abstract: This invention is directed to methods of treating diseases or conditions associated with JAK2 activity in a mammal comprising the administration of a compound of formula (I): where n, m, Y, R1, R2, R3, R4 and R5 are disclosed herein, or a pharmaceutically acceptable salt.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: April 18, 2017
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Somasekhar Bhamidipati, Jeffrey Clough, Ankush Argade, Rajinder Singh, Vadim Markovtsov, Pingyu Ding, Jiaxin Yu, Andy Atuegbu, Hui Hong, Ihab Darwish, Sambaiah Thota
  • 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use
    Publication number: 20170096409
    Abstract: The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-? superfamily such as Nodal or Activin.
    Type: Application
    Filed: April 2, 2015
    Publication date: April 6, 2017
    Inventors: Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Donald Payan, Marina Gelman, Todd Kinsella
  • Compositions and methods for inhibition of the JAK pathway
    Patent number: 9611260
    Abstract: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: April 4, 2017
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Thilo J. Heckrodt, Yan Chen, Darren John McMurtrie, Vanessa Taylor, Rajinder Singh, Pingyu Ding, Rose Yen
  • GDF-8 inhibitors
    Patent number: 9518040
    Abstract: Described are GCF-8 inhibitors of the formula (I), and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R5, R6, X and Z are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for inhibiting GDF-8 in a cell and methods for treating a patient suffering from a disease or disorder, wherein the patient would therapeutically benefit from an increase in mass or strength of muscle tissue.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: December 13, 2016
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Somasekhar Bhamidipati, Marina Gelman, Pingyu Ding, Rajinder Singh, Jeffrey Clough, Todd Kinsella, Donald Payan
  • GDF-8 Inhibitors
    Publication number: 20160264553
    Abstract: Disclosed are 2,2?-bipyridyl compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein R1, Z and n are as described herein. In certain embodiments, a compound disclosed herein inhibits GDF8, and can be used to treat disease by blocking GDF8 signaling.
    Type: Application
    Filed: February 15, 2016
    Publication date: September 15, 2016
    Inventors: Pingyu Ding, Marina Gelman, Todd Kinsella, Rajinder Singh, Somasekhar Bhamidipati, Upender Velaparthi, Robert M. Borzilleri, Hasibur Rahaman, Jayakumar Sankara Warrier
  • Compositions and methods for inhibition of the JAK pathway
    Patent number: RE47396
    Abstract: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: May 21, 2019
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Thilo J. Heckrodt, Yan Chen, Darren John McMurtrie, Vanessa Taylor, Rajinder Singh, Pingyu Ding, Rose Yen